1.45
+0.04(+2.84%)
Currency In USD
| Previous Close | 1.41 |
| Open | 1.44 |
| Day High | 1.47 |
| Day Low | 1.42 |
| 52-Week High | 3.4 |
| 52-Week Low | 0.87 |
| Volume | 400,323 |
| Average Volume | 2.74M |
| Market Cap | 145.31M |
| PE | -1.37 |
| EPS | -1.06 |
| Moving Average 50 Days | 1.56 |
| Moving Average 200 Days | 1.72 |
| Change | 0.04 |
If you invested $1000 in Alector, Inc. (ALEC) since IPO date, it would be worth $80.2 as of December 24, 2025 at a share price of $1.45. Whereas If you bought $1000 worth of Alector, Inc. (ALEC) shares 5 years ago, it would be worth $94.52 as of December 24, 2025 at a share price of $1.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
GlobeNewswire Inc.
Dec 12, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that
Alector to Participate in the Bank of America CNS Therapeutics Conference
GlobeNewswire Inc.
Dec 01, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 06, 2025 9:05 PM GMT
Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing toward IND-e